The impact of systemic psoriasis treatments on human papillomavirus activation and propagation

Abstract

Psoriasis is one of the most prevalent diseases in the world and it affects up to 2% of the worldwide population. Its pathogenesis is complex and the lesions may be triggered by multiple factors. Human papillomavirus (HPV) is associated with anogenital cancers, cutaneous warts and is considered one of the most prevalent infections in the world. In this review, the available literature on the systemic treatment of patients with psoriasis and concomitant HPV infection was analysed.

Analysis of differentially expressed genes in Verruca vulgaris <i>vs</i>. adjacent normal skin by RNA-sequencing

“…However, the relationship between HPV infection and these skin diseases remains obscure. Prior cohort studies concluded that HPV infection increased the risk of new-onset psoriasis (Tu et al, 2021;Korecka et al, 2022). Bergot confirmed that HPV 16 E7 drove the activation of TSLP and type 2 ILC infiltration to the onset of atopic dermatitis-like pathology.…”

Rapid progression of condyloma acuminatum caused by IL-17A antibody treatment: a case report

“…Additionally, skin barrier damage caused by psoriasis can increase the risk of viral infection. In this case, condyloma acuminatum partially developed at the site of psoriasis skin lesions (5). On the other hand, immune cell infiltration and inflammatory cytokines produced during psoriasis pathogenesis have antiviral effects and promote antiviral immunity (5).…”

“…Psoriasis is an chronic inflammatory skin disease in which IL-17 and IL-23 are key drivers of disease pathogenesis. Viral infection can act as a triggering factor, activating immune cells such as T lymphocytes and dendritic cells, promoting the expression of various inflammatory cytokines, and inducing or exacerbating psoriasis ( 5 ). Additionally, skin barrier damage caused by psoriasis can increase the risk of viral infection.…”

“…The impact of IL-17A monoclonal antibody treatment on HPV infection in psoriasis patients is still unclear and controversial. Some research suggests that the HPV infection rate is significantly increased in psoriasis patients treated with IL-17 monoclonal antibodies ( 7 ), while other reports indicate therapeutic effects on HPV infection ( 5 ). Specifically, when using secukinumab to treat psoriasis, there is a significant decrease in HPV virus detection and even disappearance of condyloma acuminatum in some patients ( 8 , 9 ), especially for high-risk HPV types ( 9 ).…”

Re: ‘The impact of systemic psoriasis treatments on human papillomavirus activation and propagation’—What about anal malignancies?

“…Dear Editor, We read with interest the recent review published by Koreka et al on the effects of systemic psoriasis treatments on human papillomavirus (HPV) activity. 1 The authors briefly discuss screening for high-risk HPV subtypes given their association with pre-malignant states, namely cervical intraepithelial neoplasia. We would like to draw attention to anal intraepithelial neoplasias (AIN), particularly high-grade squamous intraepithelial lesions (HSIL), and discuss the need for further research on risk and screening in patients with plaque psoriasis treated with immunosuppression.…”